WO2005111627A3 - Methods and products related to the improved analysis of carbohydrates - Google Patents

Methods and products related to the improved analysis of carbohydrates Download PDF

Info

Publication number
WO2005111627A3
WO2005111627A3 PCT/US2005/013107 US2005013107W WO2005111627A3 WO 2005111627 A3 WO2005111627 A3 WO 2005111627A3 US 2005013107 W US2005013107 W US 2005013107W WO 2005111627 A3 WO2005111627 A3 WO 2005111627A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
carbohydrates
glycosylation
analysis
glycans
Prior art date
Application number
PCT/US2005/013107
Other languages
French (fr)
Other versions
WO2005111627A2 (en
Inventor
Nishla Keiser
Carlos Bosques
Ram Sasisekharan
Pankaj Gandhe
S Raguram
Aravind Srinivasan
Original Assignee
Massachusetts Inst Technology
Nishla Keiser
Carlos Bosques
Ram Sasisekharan
Pankaj Gandhe
S Raguram
Aravind Srinivasan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology, Nishla Keiser, Carlos Bosques, Ram Sasisekharan, Pankaj Gandhe, S Raguram, Aravind Srinivasan filed Critical Massachusetts Inst Technology
Publication of WO2005111627A2 publication Critical patent/WO2005111627A2/en
Publication of WO2005111627A3 publication Critical patent/WO2005111627A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Abstract

The invention relates, in part, to the improved analysis of carbohydrates. In particular, the invention relates to the analysis of carbohydrates, such as N-glycans and O-glycans found on proteins. Improved methods, therefore, for the study of glycosylation patterns on cells, tissue and body fluids are also provided. Information regarding the analysis of glycans, such as the glycosylation patterns on cells, tissues and in body fluids, can be used in diagnostic and treatment methods as well as for facilitating the study of the effects of glycosylation/altered glycosylation on protein function. Such methods are also provided. Methods are also provided to assess protein production processes, to assess the purity of proteins produced, and to select proteins with the desired glycosylation.
PCT/US2005/013107 2004-04-15 2005-04-15 Methods and products related to the improved analysis of carbohydrates WO2005111627A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56287404P 2004-04-15 2004-04-15
US60/562,874 2004-04-15

Publications (2)

Publication Number Publication Date
WO2005111627A2 WO2005111627A2 (en) 2005-11-24
WO2005111627A3 true WO2005111627A3 (en) 2006-04-06

Family

ID=34981344

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/013107 WO2005111627A2 (en) 2004-04-15 2005-04-15 Methods and products related to the improved analysis of carbohydrates

Country Status (2)

Country Link
US (2) US20060057638A1 (en)
WO (1) WO2005111627A2 (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012726A2 (en) * 1998-08-27 2000-03-09 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase i and ii
EP1190364A2 (en) * 1999-04-23 2002-03-27 Massachusetts Institute Of Technology System and method for polymer notation
WO2001066772A2 (en) * 2000-03-08 2001-09-13 Massachusetts Institute Of Technology Heparinase iii and uses thereof
ATE426805T1 (en) * 2000-09-12 2009-04-15 Massachusetts Inst Technology METHODS AND PRODUCTS ASSOCIATED WITH LOW MOLECULAR HEPARIN
EP1328260A2 (en) * 2000-10-18 2003-07-23 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
CA2484604C (en) * 2002-05-03 2011-08-02 Massachusetts Institute Of Technology .delta. 4,5 glycuronidase and uses thereof
EP1590648A4 (en) 2002-05-20 2007-04-18 Massachusetts Inst Technology Novel method for sequence determination using nmr
JP4606712B2 (en) * 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー 2-O sulfatase compositions and related methods
US7407810B2 (en) 2003-09-04 2008-08-05 Momenta Pharmaceuticals, Inc. Methods and apparatus for characterizing polymeric mixtures
EP1737954A2 (en) * 2004-03-10 2007-01-03 The Massachusetts Institute Of Technology Recombinant chondroitinase abc i and uses thereof
US20060127950A1 (en) * 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
WO2005111627A2 (en) 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US7651847B2 (en) * 2004-06-22 2010-01-26 The Regents Of The University Of California Methods of oligosaccharide profiling for the detection of cancer
EP1768687A2 (en) * 2004-06-29 2007-04-04 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
WO2006083328A2 (en) * 2004-09-15 2006-08-10 Massachusetts Institute Of Technology Biologically active surfaces and methods of their use
US8173437B2 (en) * 2005-06-10 2012-05-08 Mannatech, Incorporated Rapid serum sugar biomarker assay of rheumatoid arthritis
US20080071148A1 (en) * 2006-04-03 2008-03-20 Massachusetts Institute Of Technology Glycomic patterns for the detection of disease
US7879799B2 (en) * 2006-08-10 2011-02-01 Institute For Systems Biology Methods for characterizing glycoproteins and generating antibodies for same
JP5294548B2 (en) * 2006-08-22 2013-09-18 株式会社日立ハイテクノロジーズ Method and apparatus for identifying sugar chain-modified protein or sugar chain-modified peptide
JP2010515434A (en) 2007-01-05 2010-05-13 マサチューセッツ インスティテュート オブ テクノロジー Compositions and methods using sulfatase from Flavobacterium heparinum
US20100151499A1 (en) * 2007-04-16 2010-06-17 Momenta Pharmaceuticals, Inc. Proteolytic release of glycans
AU2008243007A1 (en) 2007-04-16 2008-10-30 Momenta Pharmaceuticals, Inc. Characterization of N-glycans using exoglycosidases
AU2008240078B2 (en) 2007-04-16 2012-10-25 Momenta Pharmaceuticals, Inc. Multi-dimensional chromatographic methods for separating N-glycans
US8043863B2 (en) 2007-04-16 2011-10-25 Momenta Pharmaceuticals, Inc. MS methods to evaluate glycans
US20080318332A1 (en) * 2007-05-29 2008-12-25 Mechref Yehia S Disease diagnosis by profiling serum glycans
AU2009256601A1 (en) * 2008-06-11 2009-12-17 Universiteit Gent Blood serum marker for detection and diagnosis of Alzheimer's disease
WO2010058605A1 (en) * 2008-11-21 2010-05-27 国立大学法人 北海道大学 Method for evaluating state of cells
WO2010071817A2 (en) * 2008-12-19 2010-06-24 Momenta Pharmaceuticals, Inc. Characterization of o-linked glycans
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013021279A2 (en) 2011-08-10 2013-02-14 Lfb Biotechnologies Highly galactosylated antibodies
EP3502123B1 (en) * 2012-02-14 2021-10-13 The Regents Of The University Of California A composition comprising free n-glycans or deglycosylated proteins
WO2013159033A1 (en) * 2012-04-20 2013-10-24 Ezose Sciences, Inc. Biomarkers for diagnosis of diabetes and monitoring of anti-diabetic therapy
WO2013158585A1 (en) * 2012-04-20 2013-10-24 Merck Sharp & Dohme Corp. Biomarkers for monitoring intervention therapies for diabetes
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9360470B2 (en) 2012-06-26 2016-06-07 Centre Hospitalier Regional Universitaire De Lille In vitro diagnostic method for an invasive fungal infection using MALDI-TOFF mass spectrometry
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US20150368357A1 (en) 2013-02-13 2015-12-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Highly galactosylated anti-her2 antibodies and uses thereof
CA2900909A1 (en) 2013-02-13 2014-08-21 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Highly galactosylated anti-tnf-.alpha. antibodies and uses thereof
CN105263319A (en) 2013-02-13 2016-01-20 法国化学与生物科技实验室 Proteins with modified glycosylation and methods of production thereof
WO2014125382A2 (en) 2013-02-13 2014-08-21 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Cetuximab with modified glycosylation and uses thereof
WO2014133428A1 (en) * 2013-02-26 2014-09-04 Schedin Weiss Sophia Diagnosis of alzheimer disease, cognitive decline and dementia
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
EP2855533A4 (en) 2013-03-15 2015-11-25 Momenta Pharmaceuticals Inc Methods related to ctla4-fc fusion proteins
WO2014186310A1 (en) 2013-05-13 2014-11-20 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
EP3058084A4 (en) 2013-10-16 2017-07-05 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
JP6098538B2 (en) * 2014-02-03 2017-03-22 株式会社島津製作所 Glycopeptide analysis method and sugar chain structure analysis program
EP2975401B1 (en) * 2014-07-18 2019-12-25 Hexal AG Improved method of mapping glycans of glycoproteins in serum samples
EP3289364B1 (en) * 2015-04-30 2019-09-18 DH Technologies Development Pte. Ltd. Identification of glycosylation forms
AU2017381656B2 (en) 2016-12-21 2020-07-02 F. Hoffmann-La Roche Ag Re-use of enzymes in in vitro glycoengineering of antibodies
JP6850351B2 (en) 2016-12-21 2021-03-31 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ In vitro sugar chain engineering of antibodies
BR112019010294A2 (en) 2016-12-21 2019-09-03 Hoffmann La Roche method for the enzymatic production of an antibody, antibody and pharmaceutical formulation
EP3592851A1 (en) 2017-03-07 2020-01-15 H. Hoffnabb-La Roche Ag Method for discovery of alternative antigen specific antibody variants
CN110749736A (en) * 2018-07-24 2020-02-04 中国科学院大连化学物理研究所 O-GalNAc glycosylated peptide segment identification method based on chemical reaction simplification
EP4041773A1 (en) 2019-10-11 2022-08-17 Beth Israel Deaconess Medical Center, Inc. Anti-tn antibodies and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996028169A1 (en) * 1995-03-15 1996-09-19 Medical College Of Hampton Roads Glycoconjugate inhibitors of human sperm-egg binding

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH653442A5 (en) * 1982-01-29 1985-12-31 Otsuka Pharma Co Ltd Process for the determination of tumour-associated glucoside derivatives
CA1313496C (en) * 1988-04-29 1993-02-09 James Wilson Dennis Diagnostic method to screen tumors
US5607859A (en) * 1994-03-28 1997-03-04 Massachusetts Institute Of Technology Methods and products for mass spectrometric molecular weight determination of polyionic analytes employing polyionic reagents
EP0747705A1 (en) 1995-06-09 1996-12-11 Bayer Corporation Specific determination of NCA 90 glycoform in the blood of cancer patients
US6217863B1 (en) * 1995-10-30 2001-04-17 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from heparinase I
US6228654B1 (en) * 1996-05-09 2001-05-08 The Scripps Research Institute Methods for structure analysis of oligosaccharides
WO2000012726A2 (en) 1998-08-27 2000-03-09 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase i and ii
US7056504B1 (en) * 1998-08-27 2006-06-06 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II
US6844166B1 (en) * 1998-09-11 2005-01-18 Sensor Technologies Inc. Recombinant reduced valency carbohydrate binding ligands
US6610484B1 (en) * 1999-01-26 2003-08-26 Cytyc Health Corporation Identifying material from a breast duct
EP1190364A2 (en) * 1999-04-23 2002-03-27 Massachusetts Institute Of Technology System and method for polymer notation
JP3689842B2 (en) * 1999-05-28 2005-08-31 株式会社Ｊ−オイルミルズ Monosaccharide analysis method for sugar composition
WO2001066772A2 (en) * 2000-03-08 2001-09-13 Massachusetts Institute Of Technology Heparinase iii and uses thereof
WO2001092890A1 (en) 2000-05-26 2001-12-06 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Method for the analysis of picomole amounts of carbohydrates
ATE426805T1 (en) * 2000-09-12 2009-04-15 Massachusetts Inst Technology METHODS AND PRODUCTS ASSOCIATED WITH LOW MOLECULAR HEPARIN
EP1328260A2 (en) * 2000-10-18 2003-07-23 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
US20040132131A1 (en) * 2001-11-05 2004-07-08 Ofer Markman Methods for comparitive analysis of carbohydrate polymers and carbohydrate polymers identified using same
US6653067B1 (en) * 2001-02-22 2003-11-25 Isis Pharmaceuticals, Inc. Methods for identifying ligand binding sites in a biomolecule
US20030008820A1 (en) * 2001-03-27 2003-01-09 Massachusetts Institute Of Technology Methods and products related to FGF dimerization
JPWO2002077649A1 (en) * 2001-03-27 2004-07-15 帝国臓器製薬株式会社 Breast cancer diagnostics
FI20011664A (en) * 2001-08-17 2003-02-18 Carbion Oy Cancer-specific oligosaccharide sequences and their use
US20030148462A1 (en) * 2001-12-14 2003-08-07 President And Fellows Of Harvard College Dual inhibition of sister chromatid separation at metaphase
EP1495328B1 (en) 2002-04-16 2014-06-18 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. A marker for measuring liver cirrhosis
CA2484604C (en) * 2002-05-03 2011-08-02 Massachusetts Institute Of Technology .delta. 4,5 glycuronidase and uses thereof
EP1590648A4 (en) * 2002-05-20 2007-04-18 Massachusetts Inst Technology Novel method for sequence determination using nmr
AU2003243396A1 (en) * 2002-06-03 2003-12-19 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from chondroitinase b
AU2002950878A0 (en) 2002-08-20 2002-09-12 Proteome Systems Intellectual Property Pty Ltd Method for diagnosing disorders
EP1587408A4 (en) * 2002-12-20 2007-09-05 Momenta Pharmaceuticals Inc Glycan markers for diagnosing and monitoring disease
CA2508829A1 (en) * 2003-01-03 2004-07-22 Caprion Pharmaceuticals, Inc. Glycopeptide identification and analysis
JP4606712B2 (en) * 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー 2-O sulfatase compositions and related methods
US7407810B2 (en) * 2003-09-04 2008-08-05 Momenta Pharmaceuticals, Inc. Methods and apparatus for characterizing polymeric mixtures
EP1737954A2 (en) 2004-03-10 2007-01-03 The Massachusetts Institute Of Technology Recombinant chondroitinase abc i and uses thereof
WO2005110438A2 (en) 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the intracellular delivery of polysaccharides
US20060127950A1 (en) 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
WO2005111627A2 (en) 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
EP1768687A2 (en) * 2004-06-29 2007-04-04 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
WO2006083328A2 (en) 2004-09-15 2006-08-10 Massachusetts Institute Of Technology Biologically active surfaces and methods of their use
CA2594013A1 (en) 2005-01-12 2006-07-20 Massachusetts Institute Of Technology Methods and compositions related to modulating the extracellular stem cell environment
WO2006105315A2 (en) 2005-03-29 2006-10-05 Massachusetts Institute Of Technology Compositions and methods for regulating inflammatory responses
WO2006105313A2 (en) 2005-03-29 2006-10-05 Massachusetts Institute Of Technology Compositions of and methods of using oversulfated glycosaminoglycans
US20080071148A1 (en) 2006-04-03 2008-03-20 Massachusetts Institute Of Technology Glycomic patterns for the detection of disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996028169A1 (en) * 1995-03-15 1996-09-19 Medical College Of Hampton Roads Glycoconjugate inhibitors of human sperm-egg binding

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
FORNO GUILLERMINA ET AL: "N- and O-linked carbohydrates and glycosylation site occupancy in recombinant human granulocyte-macrophage colony-stimulating factor secreted by a Chinese hamster ovary cell line.", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 271, no. 5, March 2004 (2004-03-01), pages 907 - 919, XP002347926, ISSN: 0014-2956 *
KAJI HIROYUKI ET AL: "Lectin affinity capture, isotope-coded tagging and mass spectrometry to identify N-linked glycoproteins.", NATURE BIOTECHNOLOGY, vol. 21, no. 6, June 2003 (2003-06-01), pages 667 - 672, XP002347925, ISSN: 1087-0156 *
KÜSTER B ET AL: "18O-labeling of N-glycosylation sites to improve the identification of gel-separated glycoproteins using peptide mass mapping and database searching.", ANALYTICAL CHEMISTRY. 1 APR 1999, vol. 71, no. 7, 1 April 1999 (1999-04-01), pages 1431 - 1440, XP009054884, ISSN: 0003-2700 *
LANDBERG EVA ET AL: "Carbohydrate composition of serum transferrin isoforms from patients with high alcohol consumption", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 210, no. 2, 1995, pages 267 - 274, XP002347927, ISSN: 0006-291X *
LANDBERG EVA ET AL: "Changes in glycosylation of human bile-salt-stimulated lipase during lactation", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 377, no. 2, 15 May 2000 (2000-05-15), pages 246 - 254, XP009054937, ISSN: 0003-9861 *
MECHREF YEHIA ET AL: "Structural investigations of glycoconjugates at high sensitivity.", CHEMICAL REVIEWS. FEB 2002, vol. 102, no. 2, February 2002 (2002-02-01), pages 321 - 369, XP009054870, ISSN: 0009-2665 *
MORELLE WILLY ET AL: "Glycomics and mass spectrometry", CURRENT PHARMACEUTICAL DESIGN, vol. 11, no. 20, 2005, pages 2615 - 2645, XP001207547, ISSN: 1381-6128 *
RAY M: "GLYCOPROTEIN GLYCAN ANALYSIS: A NEW USP GENERAL CHAPTER", USP. CONFERENCE ON BIOLOGICAL AND BIOTECHNOLOGICAL DRUGSUBSTANCES AND PRODUCTS, XX, XX, 18 November 2003 (2003-11-18), XX, XP002347956 *
YANG SHI-XIN ET AL: "Glycosylation in human thyroglobulin: Location of the N-linked oligosaccharide units and comparison with bovine thyroglobulin", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 327, no. 1, 1996, pages 61 - 70, XP002347930, ISSN: 0003-9861 *
ZHOU GE ET AL: "Uroplakin Ia is the urothelial receptor for uropathogenic Escherichia coli: Evidence from in vitro FimH binding", JOURNAL OF CELL SCIENCE, vol. 114, no. 22, November 2001 (2001-11-01), pages 4095 - 4103, XP002347929, ISSN: 0021-9533 *

Also Published As

Publication number Publication date
US20100136599A1 (en) 2010-06-03
WO2005111627A2 (en) 2005-11-24
US20060057638A1 (en) 2006-03-16
US8000904B2 (en) 2011-08-16

Similar Documents

Publication Publication Date Title
WO2005111627A3 (en) Methods and products related to the improved analysis of carbohydrates
WO2007044471A3 (en) Methods and products related to the improved analysis of carbohydrates
AU2003295644A1 (en) Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
WO2006124644A3 (en) Protein and antibody profiling using small molecule microarrays
WO2006104610A3 (en) Trans carotenoids, their synthesis, formulation and uses
WO2007092640A3 (en) Antibodies that bind par-2
EP2428223A3 (en) Use of human cells of myeloid leukaemia origin for expression of antibodies
WO2007109221A3 (en) Methods for reducing protein aggregation
HK1114419A1 (en) Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
WO2003072734A3 (en) Bipolar trans carotenoid salts and their uses
WO2006060680A3 (en) Mda-7 protein variants having antiproliferative activity
WO2008093165A3 (en) The use of pgil ohgosaccharyltransferase for o-glycosylating proteins
WO2005040421A3 (en) Prognostic and diagnostic markers for cell proliferative disorders of the breast tissues
WO2005111204A3 (en) Porcine forssman synthetase cdna and polypeptide
WO2007038264A3 (en) Gapr-1 methods
WO2007061988A3 (en) Methods for determining notch signaling and uses thereof
WO2005000335A3 (en) Use of genes differentially expressed during aging of liver for treatment and diagnosis
WO2005047469A3 (en) PORCINE ISOGLOBOSIDE 3 SYNTHASE PROTEIN, cDNA, GENOMIC ORGANIZATION, AND REGULATORY REGION
EP2083018A3 (en) Compositions and methods relating to STOP-1
WO2005017187A3 (en) Methods for screening and identifying compounds
WO2004113574A3 (en) Methods for disease screening
WO2003046180A3 (en) Human cdnas and proteins and uses thereof
WO2007002739A3 (en) Chromium-amino acid complexes in the treatment of diabetes and other diseases
WO2007136782A3 (en) Kits and methods for evaluating misfolded proteins
WO2004005540A3 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase